Cargando…

Serum Metabolic Profiling Identifies a Biomarker Panel for Improvement of Prostate Cancer Diagnosis

OBJECTIVES: To identify and validate a biomarker panel by serum metabolic profiling for improvement of PCa diagnosis. MATERIALS AND METHODS: Totally, 134 individuals were included in this study. Among them, 39 PCa patients and 45 control patients (negative prostate biopsy) were involved in the disco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Huan, Chen, Junyi, He, Jingyi, Ji, Jin, Cao, Zhi, Chen, Xi, Xu, Yalong, He, Xing, Xu, Guowang, Zhou, Lina, Wei, Xuedong, Hou, Jianquan, Wang, Zhong, Yang, Bo, Wang, Fubo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138432/ https://www.ncbi.nlm.nih.gov/pubmed/34026644 http://dx.doi.org/10.3389/fonc.2021.666320

Ejemplares similares

Glycolytic potential enhanced by blockade of pyruvate influx into mitochondria sensitizes prostate cancer to detection and radiotherapy
por: Xu, Huan, et al.
Publicado: (2022)

Differential Expression and Prognostic Value of Cytoplasmic and Nuclear Cyclin D1 in Prostate Cancer
por: Cao, Zhi, et al.
Publicado: (2020)

FASN Protein Overexpression Indicates Poor Biochemical Recurrence-Free Survival in Prostate Cancer
por: Cao, Zhi, et al.
Publicado: (2020)

Circulating exosomal mRNA profiling identifies novel signatures for the detection of prostate cancer
por: Ji, Jin, et al.
Publicado: (2021)

A Novel Urine Exosomal lncRNA Assay to Improve the Detection of Prostate Cancer at Initial Biopsy: A Retrospective Multicenter Diagnostic Feasibility Study
por: Li, Yun, et al.
Publicado: (2021)

Long Non-Coding RNA SNHG1 Regulates the Wnt/β-Catenin and PI3K/AKT/mTOR Signaling Pathways via EZH2 to Affect the Proliferation, Apoptosis, and Autophagy of Prostate Cancer Cell
por: Chen, Junyi, et al.
Publicado: (2020)

Prostate Cancer Diagnosis Using Urine Sediment Analysis-Based α-Methylacyl-CoA Racemase Score: A Single-Center Experience
por: Ji, Jin, et al.
Publicado: (2019)

New Diagnostic Model for Clinically Significant Prostate Cancer in Biopsy-Naïve Men With PIRADS 3
por: Huang, Chen, et al.
Publicado: (2022)

Artificial intelligence for the diagnosis of clinically significant prostate cancer based on multimodal data: a multicenter study
por: Zhang, Huiyong, et al.
Publicado: (2023)

Machine learning model for the prediction of prostate cancer in patients with low prostate-specific antigen levels: A multicenter retrospective analysis
por: Deng, Xiaobin, et al.
Publicado: (2022)

Urine Exosomal AMACR Is a Novel Biomarker for Prostate Cancer Detection at Initial Biopsy
por: Jin, Xin, et al.
Publicado: (2022)

Autonomic nerve regulation for prostate cancer: study based on the tissue transcriptional analysis
por: Liu, Fang, et al.
Publicado: (2020)

KDM6B is an androgen regulated gene and plays oncogenic roles by demethylating H3K27me3 at cyclin D1 promoter in prostate cancer
por: Cao, Zhi, et al.
Publicado: (2021)

Metabolomics Profiling Discriminates Prostate Cancer From Benign Prostatic Hyperplasia Within the Prostate-Specific Antigen Gray Zone
por: Xu, Bei, et al.
Publicado: (2021)

Screening to Identify an Immune Landscape-Based Prognostic Predictor and Therapeutic Target for Prostate Cancer
por: Shen, Yanting, et al.
Publicado: (2021)

Identification of a Novel Ferroptosis-Related Gene Prognostic Signature in Bladder Cancer
por: Sun, Jiale, et al.
Publicado: (2021)

Outcomes of fertility preservation treatments in patients with endometrial cancer with different molecular classifications based on an NGS panel
por: Xu, Yan, et al.
Publicado: (2023)

MAFG-AS1 is a prognostic biomarker and facilitates prostate cancer progression
por: Li, Peizhang, et al.
Publicado: (2022)

Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas
por: Mehta, Shreya, et al.
Publicado: (2021)

Evaluation of Postoperative Radiotherapy Effect on Survival of Resected Stage III-N2 Non-small Cell Lung Cancer Patients
por: Gao, Fei, et al.
Publicado: (2020)

A new tumorgraft panel to accelerate precision medicine in prostate cancer
por: Béraud, Claire, et al.
Publicado: (2023)

Discovery and Validation of Serum MicroRNAs as Early Diagnostic Biomarkers for Prostate Cancer in Chinese Population
por: Lyu, Ji, et al.
Publicado: (2019)

Integrative Analysis of Methylation and Copy Number Variations of Prostate Adenocarcinoma Based on Weighted Gene Co-expression Network Analysis
por: Hou, Yaxin, et al.
Publicado: (2021)

Corrigendum: Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas
por: Mehta, Shreya, et al.
Publicado: (2021)

Development of a nomogram based on serum cytokine-related riskscore in breast cancer
por: Zhu, Ye, et al.
Publicado: (2023)

Percent free prostate-specific antigen for prostate cancer diagnosis in Chinese men with a PSA of 4.0–10.0 ng/mL: Results from the Chinese Prostate Cancer Consortium
por: Chen, Rui, et al.
Publicado: (2015)

A four-microRNA panel in serum may serve as potential biomarker for renal cell carcinoma diagnosis
por: Li, Rongkang, et al.
Publicado: (2023)

Diagnostic value of tumor-associated autoantibodies panel in combination with traditional tumor markers for lung cancer
por: Xu, Yu, et al.
Publicado: (2023)

Weighted gene co-expression network reveals driver genes contributing to phenotypes of anaplastic thyroid carcinoma and immune checkpoint identification for therapeutic targets
por: Dong, Xingxing, et al.
Publicado: (2022)

Prostate Microbiota and Prostate Cancer: A New Trend in Treatment
por: Che, Bangwei, et al.
Publicado: (2021)

Comparison of MRI/US Fusion Targeted Biopsy and Systematic Biopsy in Biopsy-Naïve Prostate Patients with Elevated Prostate-Specific Antigen: A Diagnostic Study
por: Huang, Chen, et al.
Publicado: (2022)

ELAVL1 promotes prostate cancer progression by interacting with other m6A regulators
por: Cai, Zhonglin, et al.
Publicado: (2022)

Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 Screening
por: Hou, Jue, et al.
Publicado: (2022)

Ten interleukins and risk of prostate cancer
por: Li, Bing-Hui, et al.
Publicado: (2023)

A 12-gene panel in estimating hormone-treatment responses of castration-resistant prostate cancer patients generated using a combined analysis of bulk and single-cell sequencing data
por: Huang, Juanlan, et al.
Publicado: (2023)

The Value of Serum Tumor Markers and Blood Inflammation Markers in Differentiating Pancreatic Serous Cystic Neoplasms and Pancreatic Mucinous Cystic Neoplasms
por: Wang, Huan, et al.
Publicado: (2022)

The role of prostate-specific antigen in the osteoblastic bone metastasis of prostate cancer: a literature review
por: Zhang, Xu, et al.
Publicado: (2023)

The preoperative neutrophil‐to‐lymphocyte ratio is not a marker of prostate cancer characteristics but is an independent predictor of biochemical recurrence in patients receiving radical prostatectomy
por: Cao, Zhi, et al.
Publicado: (2019)

LncRNA-AC068228.1 Is a Novel Prognostic Biomarker That Promotes Malignant Phenotypes in Lung Adenocarcinoma
por: Jiang, Xiulin, et al.
Publicado: (2022)

A Diagnostic Panel of DNA Methylation Biomarkers for Lung Adenocarcinoma
por: Shen, Nan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7bmc3r0aed0vual28b0tgtq2hg